Monte Rosa Therapeutics Inc
GLUE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.34B
Close$
$19.28
21.4% upside
Current Fair Value
21.4% upsideUndervalued by 21.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.34 Billion |
|---|---|
| Enterprise Value | $1.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 1.56 |
| Outstanding Shares | 101,478,945 |
Return
| Return on Equity | -33.06% |
|---|---|
| Return on Assets | -23.15% |
| Return on Invested Capital | -27.96% |
Valuation & Multiples
| P/E Ratio | -7.42 |
|---|---|
| PEG | -2.93 |
| Price to Sales | - |
| Price to Book Ratio | 3.97 |
| Enterprise Value to Revenue | 45.65 |
| Enterprise Value to EBIT | -7.46 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$12.91 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
$15.71 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.68% |
|---|---|
| Total Calls | 434▼ 99.79% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.45%▼ 113.20% |
|---|---|
| Total Invested | $308.44M▼ 78.43% |
| Investors Holding | 54▼ 141.00% |
ESG Score
No data
About Monte Rosa Therapeutics Inc
60 employees